Most initial IO clinical trials excluded patients with early-stage hormone receptor–positive and human epidermal growth factor receptor 2–negative (HR+HER2–) breast cancers, considered unlikely to respond because of low levels of immune infiltrate. The gene discussed is ERBB2; the disease is breast cancer.